Resources for Patients and their Families

Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma

Brief Summary

To Study the Effect of Polymorphisms in Fas Ligand Gene Promoter Region (rs 763110) and Fas gene (rs1800682) on Platinum-Based regimens used in treatment of malignant pleural mesothelioma (MPM)

Tracking Information
First Received DateOctober 11, 2014
Last Changed DateDecember 30, 2017
Start DateApril 2014
Actual Primary Completion DateJune 2016
Primary Outcome Measures

response rate [Time Frame: After 6 cycles of chemotherapy (each cycle is 21 days )]

Secondary Outcome Measures

progression free survival (PFS) [Time Frame: one year]

overall survival (OS) [Time Frame: one year]

estimation of treatment related toxicity [Time Frame: during the chemotherapy period, average duration 4 months]

Descriptive Information
Study TypeObservational
  • Malignant Pleural Mesothelioma
Study Arms / Comparison Groups0 / 2
Detailed Description

This study tries to find a correlation between single nucleotide polymorphisms (SNP) found in promoter region of Fas Ligand gene (rs 763110) and Fas (rs1800682) and clinical outcome on patients with MPM treated with platinum-Based agents as first line. the patients will have one of three following genotypes : Thymine/Thymine, Thymine/Cytosine or Cytosine/Cytosine (for Fas ligand polymorphism) and Adenine/Adenine, Adenine/Guanine or Guanine/Guanine ( for Fas polymorphism).

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment68
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Patients with histologically confirmed Malignant Pleural Mesothelioma

- Age of 18 years or more.

- first-line chemotherapy with platinum-Based agents

Exclusion Criteria:

- history of prior malignancy.

- pregnancy or lactation or any other reason preventing him from taking platinum-Based chemotherapy (AST more than 2.5* Upper Limit of Normal or Serum bilirubin more than 1.5* Upper Limit of Normal)

Administrative Information
Responsible PartyPrincipal Investigator
SponsorAin Shams University
Verification DateDecember 2017
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog



What Does Cancer Remission Mean?

Diagnosing Diffuse Mesothelioma with Novel Biomarker CD47

Nicholas Hondrogen: A Prolific Art Career Abruptly Ended by Mesothelioma

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: